Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors

NCT05438420 is registered in ClinicalTrials.gov with Qurient Co., Ltd. as lead sponsor.

NCT NCT05438420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
Lead sponsor
Qurient Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 12, 2023
Completion date
March 30, 2028
Enrollment
120 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, esophageal cancer, gastric cancer, hepatocellular cancer